Tonix Total Stockholder Equity vs Non Currrent Assets Other Analysis

TNXP Stock

USD 0.19 0.01 5.00%

Tonix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Tonix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tonix Pharmaceuticals is a good investment. Please check the relationship between Tonix Pharmaceuticals Total Stockholder Equity and its Non Currrent Assets Other accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Total Stockholder Equity vs Non Currrent Assets Other

Total Stockholder Equity vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tonix Pharmaceuticals Total Stockholder Equity account and Non Currrent Assets Other. At this time, the significance of the direction appears to have no relationship.

The correlation between Tonix Pharmaceuticals' Total Stockholder Equity and Non Currrent Assets Other is 0.08. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Tonix Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Tonix Pharmaceuticals' Total Stockholder Equity and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Tonix Pharmaceuticals Holding are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Total Stockholder Equity i.e., Tonix Pharmaceuticals' Total Stockholder Equity and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.08

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from Tonix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tonix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

At this time, Tonix Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 11/24/2024, Enterprise Value Over EBITDA is likely to grow to 0.08, while Enterprise Value is likely to drop (8.7 M).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	92.3M	112.1M	121.4M	127.5M
Cost Of Revenue	92.3M	112.1M	4.7M	4.5M

Total Operating Expenses Cost Of Revenue

Tonix Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Short Long Term Debt Total	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt
Total Assets		0.83	0.96	0.94	-0.8	-0.84	0.86	0.85	0.83	0.92	0.59	0.23	0.92	0.73	0.89	0.69	0.88	0.42	0.89	0.94	0.86	0.69	0.84	0.11	0.57	0.68
Other Current Liab	0.83		0.92	0.62	-0.34	-0.94	0.44	0.43	0.64	0.96	0.93	0.14	0.94	0.97	0.5	0.33	0.51	0.82	0.89	0.96	0.97	0.61	0.98	0.07	0.2	0.69
Total Current Liabilities	0.96	0.92		0.85	-0.66	-0.91	0.73	0.73	0.8	0.97	0.73	0.27	0.96	0.86	0.78	0.63	0.81	0.59	0.93	0.98	0.91	0.68	0.9	0.15	0.5	0.74
Total Stockholder Equity	0.94	0.62	0.85		-0.92	-0.68	0.94	0.94	0.85	0.77	0.33	0.25	0.77	0.49	0.96	0.75	0.94	0.14	0.76	0.8	0.69	0.7	0.65	0.08	0.64	0.56
Net Debt	-0.8	-0.34	-0.66	-0.92		0.42	-0.99	-0.99	-0.74	-0.54	0.0	-0.17	-0.55	-0.2	-0.98	-0.86	-0.94	0.16	-0.57	-0.57	-0.4	-0.55	-0.36	0.01	-0.78	-0.42
Retained Earnings	-0.84	-0.94	-0.91	-0.68	0.42		-0.5	-0.49	-0.61	-0.92	-0.85	-0.27	-0.99	-0.91	-0.56	-0.36	-0.58	-0.72	-0.92	-0.94	-0.92	-0.51	-0.93	-0.22	-0.21	-0.82
Cash	0.86	0.44	0.73	0.94	-0.99	-0.5		0.99	0.77	0.62	0.11	0.17	0.63	0.31	0.99	0.87	0.96	-0.05	0.65	0.65	0.49	0.58	0.45	0.01	0.78	0.48
Cash And Short Term Investments	0.85	0.43	0.73	0.94	-0.99	-0.49	0.99		0.76	0.61	0.1	0.27	0.62	0.3	0.99	0.86	0.96	-0.07	0.63	0.65	0.47	0.59	0.43	0.02	0.78	0.45
Net Receivables	0.83	0.64	0.8	0.85	-0.74	-0.61	0.77	0.76		0.76	0.39	0.13	0.69	0.53	0.81	0.69	0.79	0.26	0.8	0.74	0.65	0.82	0.63	0.05	0.45	0.54
Common Stock Total Equity	0.92	0.96	0.97	0.77	-0.54	-0.92	0.62	0.61	0.76		0.83	0.11	0.95	0.91	0.66	0.53	0.69	0.71	0.94	0.99	0.97	0.63	0.96	0.18	0.39	0.73
Common Stock Shares Outstanding	0.59	0.93	0.73	0.33	0.0	-0.85	0.11	0.1	0.39	0.83		0.06	0.81	0.97	0.17	0.06	0.21	0.95	0.75	0.82	0.89	0.39	0.91	0.13	-0.04	0.6
Short Term Investments	0.23	0.14	0.27	0.25	-0.17	-0.27	0.17	0.27	0.13	0.11	0.06		0.26	0.15	0.29	0.09	0.28	-0.02	0.15	0.2	0.1	0.22	0.1	0.26	0.07	0.11
Other Stockholder Equity	0.92	0.94	0.96	0.77	-0.55	-0.99	0.63	0.62	0.69	0.95	0.81	0.26		0.89	0.67	0.46	0.68	0.65	0.95	0.97	0.94	0.57	0.93	0.19	0.32	0.8
Total Liab	0.73	0.97	0.86	0.49	-0.2	-0.91	0.31	0.3	0.53	0.91	0.97	0.15	0.89		0.37	0.29	0.41	0.91	0.85	0.91	0.91	0.49	0.93	0.14	0.18	0.68
Total Current Assets	0.89	0.5	0.78	0.96	-0.98	-0.56	0.99	0.99	0.81	0.66	0.17	0.29	0.67	0.37		0.86	0.97	0.0	0.68	0.7	0.53	0.63	0.49	0.04	0.76	0.5
Common Stock	0.69	0.33	0.63	0.75	-0.86	-0.36	0.87	0.86	0.69	0.53	0.06	0.09	0.46	0.29	0.86		0.88	0.02	0.57	0.54	0.31	0.45	0.29	0.13	0.92	0.43
Accounts Payable	0.88	0.51	0.81	0.94	-0.94	-0.58	0.96	0.96	0.79	0.69	0.21	0.28	0.68	0.41	0.97	0.88		0.05	0.69	0.71	0.55	0.61	0.52	0.13	0.81	0.56
Short Long Term Debt Total	0.42	0.82	0.59	0.14	0.16	-0.72	-0.05	-0.07	0.26	0.71	0.95	-0.02	0.65	0.91	0.0	0.02	0.05		0.64	0.69	0.75	0.2	0.78	0.14	-0.08	0.53
Other Liab	0.89	0.89	0.93	0.76	-0.57	-0.92	0.65	0.63	0.8	0.94	0.75	0.15	0.95	0.85	0.68	0.57	0.69	0.64		0.93	0.87	0.58	0.87	0.21	0.35	0.86
Net Tangible Assets	0.94	0.96	0.98	0.8	-0.57	-0.94	0.65	0.65	0.74	0.99	0.82	0.2	0.97	0.91	0.7	0.54	0.71	0.69	0.93		0.96	0.64	0.95	0.12	0.41	0.72
Property Plant And Equipment Net	0.86	0.97	0.91	0.69	-0.4	-0.92	0.49	0.47	0.65	0.97	0.89	0.1	0.94	0.91	0.53	0.31	0.55	0.75	0.87	0.96		0.58	1.0	0.16	0.2	0.69
Current Deferred Revenue	0.69	0.61	0.68	0.7	-0.55	-0.51	0.58	0.59	0.82	0.63	0.39	0.22	0.57	0.49	0.63	0.45	0.61	0.2	0.58	0.64	0.58		0.57	-0.16	0.31	0.27
Non Current Assets Total	0.84	0.98	0.9	0.65	-0.36	-0.93	0.45	0.43	0.63	0.96	0.91	0.1	0.93	0.93	0.49	0.29	0.52	0.78	0.87	0.95	1.0	0.57		0.16	0.18	0.69
Non Currrent Assets Other	0.11	0.07	0.15	0.08	0.01	-0.22	0.01	0.02	0.05	0.18	0.13	0.26	0.19	0.14	0.04	0.13	0.13	0.14	0.21	0.12	0.16	-0.16	0.16		0.07	0.28
Other Assets	0.57	0.2	0.5	0.64	-0.78	-0.21	0.78	0.78	0.45	0.39	-0.04	0.07	0.32	0.18	0.76	0.92	0.81	-0.08	0.35	0.41	0.2	0.31	0.18	0.07		0.26
Long Term Debt	0.68	0.69	0.74	0.56	-0.42	-0.82	0.48	0.45	0.54	0.73	0.6	0.11	0.8	0.68	0.5	0.43	0.56	0.53	0.86	0.72	0.69	0.27	0.69	0.28	0.26

Click cells to compare fundamentals

Tonix Pharmaceuticals Account Relationship Matchups

Tonix Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.6M	98.2M	240.9M	225.7M	154.5M	162.2M
Other Current Liab	1.0M	2.5M	5.1M	6.4M	9.5M	10.0M
Total Current Liabilities	5.1M	9.8M	21.7M	18.2M	18.9M	19.8M
Total Stockholder Equity	9.4M	87.6M	218.7M	207.2M	105.5M	53.9M
Net Debt	(10.9M)	(75.8M)	(177.7M)	(119.5M)	(15.1M)	(15.9M)
Retained Earnings	(217.1M)	(267.5M)	(359.8M)	(470.0M)	(600.7M)	(570.6M)
Cash	11.2M	77.1M	178.7M	120.2M	24.9M	37.7M
Cash And Short Term Investments	11.2M	77.1M	178.7M	120.2M	24.9M	39.9M
Net Receivables	1.0M	7.6M	7.7M	8.0M	6.1M	3.8M
Common Stock Total Equity	3K	9K	206K	496K	570.4K	598.9K
Common Stock Shares Outstanding	8.0K	14.8K	56.9K	182.5K	532.5K	559.1K
Liabilities And Stockholders Equity	14.6M	98.2M	240.9M	225.7M	154.5M	162.2M
Other Stockholder Equity	226.5M	355.0M	578.6M	677.3M	706.4M	741.7M
Total Liab	5.1M	10.5M	22.2M	18.5M	48.9M	51.4M
Total Current Assets	13.9M	88.0M	189.0M	130.8M	47.8M	44.4M
Common Stock	9K	206K	496K	76K	59K	67.6K
Accounts Payable	3.1M	4.6M	13.3M	8.1M	3.8M	3.2M
Net Tangible Assets	9.3M	87.5M	218.7M	207.2M	238.3M	250.2M
Property Plant And Equipment Net	390K	9.8M	51.5M	94.5M	94.9M	99.6M
Current Deferred Revenue	704K	2.2M	2.8M	3.3M	3.0M	1.7M
Non Current Assets Total	610K	10.2M	51.9M	94.9M	106.7M	112.0M
Retained Earnings Total Equity	(188.5M)	(217.1M)	(267.5M)	(359.8M)	(323.8M)	(307.6M)
Non Current Liabilities Total	6K	716K	467K	328K	30.0M	31.6M
Capital Surpluse	212.2M	226.5M	355.0M	578.1M	664.9M	698.1M
Other Current Assets	2.7M	3.3M	2.7M	10.5M	2.6M	2.2M
Property Plant And Equipment Gross	390K	9.8M	51.9M	96.2M	100.2M	105.2M
Accumulated Other Comprehensive Income	(46K)	(62K)	(92K)	(167K)	(232K)	(220.4K)
Property Plant Equipment	34K	9.8M	51.5M	94.5M	108.7M	114.1M
Net Invested Capital	9.4M	87.6M	218.7M	207.2M	112.1M	107.4M
Net Working Capital	8.8M	78.2M	167.3M	112.6M	28.9M	27.4M
Capital Stock	9K	206K	496K	76K	59K	56.1K

Pair Trading with Tonix Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tonix Stock

0.61

VALN

Valneva SE ADR

Pair Corr

Moving against Tonix Stock

0.63

NXGLW

NexGel Warrant

Pair Corr

The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.

The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Tonix Stock Analysis

When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC